☆ 4.7 Review

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

VACCINES (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine

Giuseppe Carli et al.

INTERNAL AND EMERGENCY MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Viral Variants-Tackling a Moving Target

John R. Mascola et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Kimberly G. Blumenthal et al.

Summary: This study investigates the occurrence of acute allergic reactions to mRNA COVID-19 vaccines among healthcare employees in Massachusetts.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

添加到收藏夹

Article Immunology

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Laurence Chu et al.

Summary: The study evaluated the safety and immunogenicity of the mRNA-1273 vaccine in healthy adults, showing significant immune responses to SARS-CoV-2 with acceptable safety profile. This vaccine induced higher antibody levels at a 100 mg dose, confirming its immunogenicity and safety for use in a 2-dose regimen.

VACCINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

添加到收藏夹

Review Immunology

Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations

Nicholas G. Kounis et al.

Summary: Vaccines are highly effective in public health, but can trigger allergic reactions, particularly severe ones that activate mast cells and lead to anaphylactic shock. Allergic reactions to vaccines are typically caused by excipients rather than the active vaccine itself.

VACCINES (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Microbiology

Coronavirus biology and replication: implications for SARS-CoV-2

Philip V'kovski et al.

Summary: This review discusses key aspects of coronavirus biology and their implications for SARS-CoV-2 infections, treatment, and prevention strategies. Understanding virus-host interactions at the molecular level is crucial for developing effective intervention strategies. Summarizing the discoveries of SARS-CoV-2 infection and comparing it with other coronaviruses will support future preparedness and combat strategies.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Kuldeep Dhama et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Immunology

COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning

Edison Ong et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

添加到收藏夹

Editorial Material Chemistry, Physical

Next-generation vaccine platforms for COVID-19

Debby van Riel et al.

NATURE MATERIALS (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Review Immunology

Adjuvants for Coronavirus Vaccines

Zhihui Liang et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

A systematic review of SARS-CoV-2 vaccine candidates

Yetian Dong et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

mRNA vaccines - a new era in vaccinology

Norbert Pardi et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Medicine, General & Internal

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

David Moher et al.

SYSTEMATIC REVIEWS (2015)

添加到收藏夹

Review Immunology

Virus-like particles in vaccine development

Antonio Roldao et al.

EXPERT REVIEW OF VACCINES (2010)

添加到收藏夹

Article Medicine, General & Internal

Comparison of two methods to detect publication bias in meta-analysis

JL Peters et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)

添加到收藏夹

Article Mathematical & Computational Biology

Quantifying heterogeneity in a meta-analysis

JPT Higgins et al.

STATISTICS IN MEDICINE (2002)

添加到收藏夹

Article Medicine, General & Internal

Empirical assessment of effect of publication bias on meta-analyses

AJ Sutton et al.

BMJ-BRITISH MEDICAL JOURNAL (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.